Taking into account the reduced availability of cystatin-C in routine laboratories and the cost, its usefulness as a prognostic factor should only be considered in patients with moderate degrees of renal dysfunction and it is advisable to continue using the classical eGFR formulas. This evidence concerns the gene CST3 and Abnormal renal physiology.